SFA Therapeutics logo

SFA Therapeutics

Emerging

Oral Treg modulator biotech with positive Phase 1b psoriasis safety data; $9.13M raised from Savantus Ventures competing in autoimmune therapy with a restore-immune-balance mechanism.

30
AI Score
Grade D↑ Trending
AI Visibility Score (Beta)
HealthcareWebsiteUpdated March 2026

Company Overview

About SFA Therapeutics

SFA Therapeutics is a Philadelphia-based clinical-stage biotech developing oral small molecule drugs that modulate regulatory T cells (Tregs) — the immune system's natural suppressor cells — to restore immune homeostasis in autoimmune diseases and cancer without the broad immunosuppression that existing biologics and small molecule therapies cause. The company raised $9.13 million from investors including Savantus Ventures and Ben Franklin Technology Partners, announced positive Phase 1b safety data for SFA-002 in psoriasis in March 2025, and received a 2025 Prix Galien USA Best Startup award nomination.

Business Model & Competitive Advantage

SFA Therapeutics' Treg modulator approach targets a fundamentally different mechanism than approved autoimmune drugs: rather than blocking specific inflammatory cytokines (like TNF inhibitors) or broadly depleting immune cells (like many chemotherapy agents), SFA-002 and related compounds selectively increase the activity or number of Tregs — the cells that naturally regulate immune responses and prevent autoimmunity. This "restore natural balance" mechanism could potentially treat autoimmune diseases while preserving normal immune function more completely than current approaches.

Competitive Landscape 2025–2026

In 2025, SFA competes in the autoimmune drug discovery and Treg biology space with Sonoma Biotherapeutics, Quell Therapeutics (Treg cell therapy), Cue Biopharma (Treg-stimulating biologics), and the established small molecule immunology companies (AbbVie with Humira/Skyrizi, Pfizer with Xeljanz) for autoimmune disease treatment. The Treg biology field has generated significant scientific interest — if oral small molecules can selectively activate Tregs without causing immunosuppression or infection risk, the therapeutic window for autoimmune diseases could be dramatically expanded. Psoriasis Phase 1b safety data is the first human clinical validation of the approach. The 2025 strategy focuses on advancing SFA-002 through Phase 2 proof-of-concept trials in psoriasis, exploring additional autoimmune indications (rheumatoid arthritis, inflammatory bowel disease), and building the chemistry platform for next-generation Treg modulators.

Curated content • Fact-checked and verified

Recent Activity

View all →

Key Differentiators

Emerging Innovator

SFA Therapeutics is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

Estimated Visibility Trend (Beta)

Simulated 8-week rolling score

30
↑ Trending

Based on estimated brand signals. Historical tracking coming soon.

Similar Brands

Browser Use logo

Browser Use

Developer Tools
B2bDeveloper ToolsPlatformSaasStartup

Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom

athenahealth logo

athenahealth

Healthcare
B2bCloud NativeEnterpriseErpHealthtechNorth AmericaSaas

athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on

Veeva Systems logo

Veeva Systems

Healthcare Tech
B2bHealthtechSaasPublic

Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv

Oracle Health logo

Oracle Health

Healthcare
HealthtechNorth AmericaB2b

Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve

Idexx Laboratories logo

Idexx Laboratories

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu

Revvity logo

Revvity

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid

For SFA Therapeutics

Claim This Profile

Are you from SFA Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim SFA Therapeutics Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention SFA Therapeutics vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →